ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Elanco Animal Health Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.49−0.06 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $11.88B
- P/E (TTM)
- –
- Dividend yield
- –
Elanco Animal Health Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Farm Animal: | $2.36B | $2.25B | $2.27B | $2.22B | $2.33B | $1.84B | $1.86B | – | – | – | 50.1% | +5.0% |
| Pet Health | $2.30B | $2.14B | $2.10B | $2.14B | $2.35B | $1.36B | $1.14B | – | – | – | 48.8% | +7.3% |
| Cattle | $1.13B | $1.01B | $949.00M | $944.00M | $980.00M | – | – | – | – | – | 23.9% | +11.7% |
| Poultry | $858.00M | $796.00M | $765.00M | $716.00M | $744.00M | – | – | – | – | – | 18.2% | +7.8% |
| Swine | $379.00M | $366.00M | $382.00M | $384.00M | $464.00M | – | – | – | – | – | 8.0% | +3.6% |
| Contract Manufacturing and Other | $53.00M | $46.00M | $42.00M | $54.00M | $82.00M | $80.00M | $80.00M | $93.90M | – | – | 1.1% | +15.2% |
| Aqua | $0 | $81.00M | $175.00M | $175.00M | $144.00M | – | – | – | – | – | 0.0% | -100.0% |
| Food Animal Ruminants & Swine | – | – | – | – | – | – | $1.11B | $1.17B | $1.18B | $1.31B | – | – |
| Companion Animal Disease Prevention | – | – | – | – | – | – | $787.90M | $804.60M | $660.20M | $628.40M | – | – |
| Strategic Exits(1) | – | – | – | – | – | – | – | $93.90M | $143.80M | $89.50M | – | – |
| Food Animal Future Protein & Health | – | – | – | – | – | – | $745.10M | $711.20M | $649.20M | $630.80M | – | – |
| Companion Animal Therapeutics | – | – | – | – | – | – | $348.00M | $283.10M | $260.80M | $255.60M | – | – |
| Strategic Exits | – | – | – | – | – | – | $79.70M | $93.90M | $143.80M | – | – | – |
| Farm Animal Ruminants & Swine | – | – | – | – | – | $1.10B | $1.11B | $1.17B | – | – | – | – |
| Farm Animal Future Protein & Health | – | – | – | – | – | $734.10M | $745.10M | $711.20M | – | – | – | – |
| Pet Health Disease Prevention | – | – | – | – | – | $992.70M | $787.90M | $804.60M | – | – | – | – |
| Pet Health Therapeutics | – | – | – | – | – | $365.80M | $348.00M | $283.10M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $2.48B | $2.40B | $2.43B | $2.45B | $2.64B | $1.80B | $1.55B | $1.58B | $1.52B | $1.55B | 52.6% | +3.2% |
| United States | $2.23B | $2.04B | $1.98B | $1.97B | $2.12B | $1.48B | $1.53B | $1.48B | $1.37B | $1.36B | 47.4% | +9.7% |
From the segment and revenue-disaggregation notes of Elanco Animal Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.